Abstract
Platinum compounds are very effective drugs for the treatment of childhood malignancies and their use has contributed to an increase in the long-term survival of children with cancer. Unfortunately the risk of severe disabling effects such as nephro- and ototoxicity is well known among children receiving platinum-based chemotherapy as part of their treatment. Data from literature suggest that very young children are more prone to develop cochlear damage especially when cranial radiotherapy or high cumulative doses are administered.
In view of the increasing number of children safely cured of their tumors it is fundamental that children treated with platinum drugs receive careful, continued, long-term followup.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gilmer Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005;23:8588–96.
English MW, Skinner R, Pearson ADJ, et al. Dose-related nephrotoxicity of carboplatin in children. Br J Cancer 1999;81:336–41.
Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 2002;59:1914–27.
Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573–84.
Micetich KC, Barnes D, Erickson LC. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. Cancer Res 1995;45:4043–7.
Knox RJ, Friedlos F, Lydall DA, et al. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedi-carboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986;46:1972–9.
Gormley PE, Bull JM, LeRoy AF, et al. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 1979;25:351–7.
DeConti RC, Toftness BR, Lange RC, et al. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 1973;33:1310–5.
Pratt CB, Hayes A, Green AA, et al. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumours: a phase II study. Cancer Treat Rep 1981;65:1021–6.
Riccardi R, Riccardi A, Di Rocco C, et al. Cerebrospinal fluid pharmacokinetics of carbopla-tin in children with brain tumors. Cancer Chemother Pharmacol 1992;30:21–4.
LI Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004;40:2445–51.
Kretschmar CS, Warren MP, Lavally BL, et al. Ototoxicity of pre-radiation cisplatin for children with central nervous system tumors. J Clin Oncol 1990;8:1191–8.
Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, et al. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer 2006;47:183–93.
Gratton MA, Smyth BJ. Cisplatin. Continuous versus bolus. J Pediatr Hematol Oncol 2006;28:60–1.
Murakami T, Inoue S, Sasaki K, et al. Studies on age-dependent plasma platinum pharmacoki-netics and ototoxicity of cisplatin. Sel Cancer Ther 1990;6:145–51.
Stöhr W, Paulides M, Bielack S, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 2007;48:140–7.
Riedemann L, Lanvers C, Deuster D, et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 2008;8:23–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Ruggiero, A., Riccardi, R. (2009). Platinum Drugs in Children with Cancer. In: Bonetti, A., Leone, R., Muggia, F.M., Howell, S.B. (eds) Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-459-3_41
Download citation
DOI: https://doi.org/10.1007/978-1-60327-459-3_41
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-458-6
Online ISBN: 978-1-60327-459-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)